SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 4/16/2015 1:11:01 PM - Followers: 193 - Board type: Free - Posts Today: 0



   
 



http://www.rexahn.com/cms/     

http://finance.yahoo.com/q/ks?s=RNN

About

Rexahn’s goal is to be a world leader in the discovery and development of new drugs to treat cancer. By developing compounds which specifically target cancer cells, excluding healthy tissue, Rexahn’s drug candidates may demonstrate increased efficacy and reduced toxicity- efficacy against multiple drug resistant cancer cells and synergism with existing cytotoxic compounds. Utilizing a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling, nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Rexahn’s core scientific expertise in the understanding of signal transduction processes involved in cancer cell growth is producing a drug portfolio with significant potential clinical value.
 

Today, our clinical development pipeline consists of three novel compounds:

Archexin® (Phase IIa) a best-in-class compound that blocks both the activated and native forms of Akt1 and has FDA orphan drug designation for the treatment of pancreatic cancer, ovarian cancer, stomach cancer, RCC, and glioblastoma.

RX-3117 (Phase I) a best-in-class compound that inhibits DNA and RNA synthesis, and exhibits high oral bioavailability. In comparison, RX-3117 may have a better safety profile than gemcitabine, the current first-line therapy for pancreatic and other cancers.

SupinoxinTM (RX-5902) (Phase I) a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis.

These lead clinical drugs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company- one with the expertise to develop cures for significant diseases of our time.
 

Rexahn Pipeline


 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
   Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
Wiki
RNN News: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/17/2015 04:15:20 PM
RNN News: Proxy Statement (definitive) (def 14a) 04/14/2015 04:50:58 PM
RNN News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 03/30/2015 04:40:09 PM
RNN News: Rexahn Pharmaceuticals reports FY14 results 03/17/2015 09:12:47 AM
RNN News: Statement of Changes in Beneficial Ownership (4) 02/04/2015 04:49:21 PM
News News Alert: Additional Proxy Soliciting Materials (definitive) (defa14a) 04/17/2015 04:15:20 PM
PostSubject
#2964   That may be true to some extent, but fan_of_flux 04/16/15 01:11:01 PM
#2963   All the stock split is go to do ttubular 04/16/15 12:45:07 PM
#2962   Looks like the Company wants to increase the fan_of_flux 04/16/15 12:15:35 PM
#2961   I agree hope it moves soon over due ttubular 04/10/15 01:02:19 PM
#2960   Sure would be nice to see this start Maverick587 04/10/15 11:57:43 AM
#2959   It was a buy ttubular 04/09/15 02:29:03 PM
#2958   125k-buy or sell? This feels like 1965 decouverte d Elbe 04/09/15 02:13:44 PM
#2957   Maybe something is going to happen soon ttubular 04/09/15 12:59:39 PM
#2956   Wow did u c that 125000 share go through ttubular 04/09/15 12:58:59 PM
#2955   I've been watching this paint dry since 2011.... DorianGray 04/02/15 11:15:18 PM
#2954   That depends on the paint. It was pretty decouverte d Elbe 04/01/15 04:06:32 PM
#2953   Yeah - almost as bad as watching paint Maverick587 04/01/15 03:49:30 PM
#2952   still holding. and waiting. and yawn..waiting. decouverte d Elbe 04/01/15 02:39:06 PM
#2951   YW...good luck to us all ;-) Theo 03/20/15 01:56:12 PM
#2950   Theo, Thanks for the positive news. thealias2002 03/20/15 01:47:11 PM
#2949   Yup. finance.yahoo.com/news/mlv-co-initiates-coverage-rexahn-142620180.html Theo 03/20/15 01:05:06 PM
#2948   Up almost 10% today with above avg volume. thealias2002 03/20/15 11:56:57 AM
#2947   In watching from the sidelines, mid .65's & Woulfe 03/18/15 02:39:58 PM
#2946   Phony bid support at every penny. This stock decouverte d Elbe 03/18/15 01:20:37 PM
#2945   finance.yahoo.com/news/rexahn-pharmaceuticals-present-12th-annual-130000743 Theo 03/18/15 09:42:32 AM
#2944   This belongs in the low 70s high 60s Woulfe 03/13/15 11:15:21 PM
#2943   He keeps posting his stupid stock on other boards. GDCT CAPITAL 03/13/15 06:07:53 PM
#2942   What does that mean ttubular 03/13/15 06:07:04 PM
#2941   Shhhh GDCT CAPITAL 03/13/15 04:36:34 PM
#2939   When is the moving out of the .70s Maverick587 03/13/15 01:35:20 AM
#2936   Never mind. decouverte d Elbe 03/10/15 09:37:15 AM
#2935   I own 50 k already waiting for news ttubular 03/09/15 01:58:43 PM
#2934   Sale ends soon! Bring your trade in!! decouverte d Elbe 03/09/15 01:33:21 PM
#2933   If u want a legendary week Rnnneeds has ttubular 03/09/15 11:11:09 AM
#2932   If u want a legendary week Rnnneeds to ttubular 03/09/15 11:09:09 AM
#2931   RNN- Let's make this a legendary week! decouverte d Elbe 03/09/15 10:39:50 AM
#2930   bought 2500@ .7517 EOD. Wanted 10,000 shares with decouverte d Elbe 03/06/15 04:12:51 PM
#2929   I love a CMF crossover. We should have jevansac 03/05/15 07:20:58 AM
#2928   Possible sleeper here could awaken soon. Eyes on it! harry crumb 03/04/15 12:10:08 PM
#2927   Charts getting primed. 50ma will cross 200ma within bud_fox 03/03/15 07:53:37 AM
#2926   it is my friend... load your machine Updated 03/02/15 10:02:48 PM
#2925   Check the chart below link: hopester 02/27/15 12:55:05 PM
#2924   Is it time? decouverte d Elbe 02/27/15 10:13:52 AM
#2923   Charts look primed for a breakout......I just don't DorianGray 02/27/15 08:38:48 AM
#2922   Y do u say that ttubular 02/26/15 10:28:58 PM
#2921   it's time my friend... it is about to Updated 02/26/15 09:21:32 PM
#2920   For what? kingsorcerer 02/26/15 09:20:48 PM
#2919   are you ready? Updated 02/25/15 10:26:22 PM
#2918   Could be accumulation but too early for any hopester 02/11/15 07:35:42 AM
#2917   I believe it is accumulation. Higher trading range johnkenny 02/10/15 10:00:01 PM
#2916   Action turned around. I was wrong, looks like decouverte d Elbe 02/10/15 04:48:06 PM
#2915   Sold early this morning. Conference was fine, but decouverte d Elbe 02/10/15 10:28:58 AM
#2914   Rexahn Pharmaceuticals to Present at the 17th Annual decouverte d Elbe 02/10/15 12:27:27 AM
#2913   Rexahn Pharma Offers Publication of Preclinical Data for decouverte d Elbe 02/10/15 12:25:33 AM
#2912   Benaim Ely decouverte d Elbe 02/10/15 12:23:38 AM
PostSubject